Prognostic Subgroups among Patients with Stage II Colon Cancer.
Level V
Where this comes from
- Record sourced from PubMed, PMID 26789877.
- Also identified by DOI 10.1056/NEJMe1514353 and PMC identifier 4852473.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Colon cancer has traditionally been treated surgically. However, many cases of colon cancer are systemic at the time of diagnosis, and apparently curative surgery is followed at a later date by tumor recurrence as a consequence of circulating tumor cells before the surgery. Adjuvant medical therapies are designed to prevent recurrences after surgical resection. The current standard for clinical prognostication relies principally on pathological staging. In early-stage colon cancers (stages I and II), all the tumor is contained within the wall of the colon. Less than 10% of patients with stage I disease have a recurrence, and adjuvant chemotherapy is . . .
Medical subject headings
- Antineoplastic Agents
- Biomarkers, Tumor
- Colonic Neoplasms
- Gene Expression
- Homeodomain Proteins